scPharmaceuticals’ Furoscix (furosemide injection) Receives the US FDA’s Approval for the At-Home Treatment of Congestion in Chronic Heart Failure
Shots:
- The US FDA has approved Furoscix (80mg/10mL) for congestion due to fluid overload in adults with NYHA Class II/III chronic HF
- Furoscix (SC infusion) demonstrated 99.6% bioavailability & 8hr. urine output of 2.7L similar to IV furosemide. The P-II (AT HOME-HF) pilot study evaluates furosemide (80mg/10mL) vs SoC in 51 patients with chronic HF with congestion uncontrolled by diuresis & showed a 37% lower risk of HF hospitalization @30 days & the 2EPs showed greater declines in mean patient body weight from baseline to day 2 & improvements in pulmonary-related metrics
- Furosemide is not indicated for use in emergency situations or in patients with APE. The formulation of furosemide is administered via On-Body Infusor & the product is expected to launch in Q1’23
Ref: Globenewswire | Image: scPharmaceuticals
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
